Evidence map›Paper›PMID 42799769›Full record

ReviewArchives of microbiology2026

Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.

Helal F Hetta, Fawaz E Alanazi, Hanan Alshareef, Ghareb M Soliman, Sultan A Almadi, Ageel F Aljuhani, Salwa Qasim Bukhari, Zinab Alatawi, Noura H Abd Ellah, Ali M Atoom and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Helal F HettaDivision of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.ORCID http://orcid.org/0000-0001-8541-7304
Fawaz E AlanaziDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Hanan AlshareefPharmacy Practice Department, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Ghareb M SolimanDepartment of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Sultan A AlmadiPharmD Students, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Ageel F AljuhaniPharmD Students, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Salwa Qasim BukhariDepartment of Diagnostic Radiology, Faculty of Medicine, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Zinab AlatawiDepartment of Family and Community Medicine, Faculty of Medicine, University of Tabuk, 47512, Tabuk, Saudi Arabia.
Noura H Abd EllahDepartment of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut, 71515, Egypt.
Ali M AtoomFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.ORCID http://orcid.org/0000-0001-9742-4253
Mahmoud El-MaghrabeyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, 71491, Tabuk, Saudi Arabia.
Yasmin N RamadanDepartment of Microbiology and Immunology, Faculty of Pharmacy, Assiut University, Assiut, 71515, Egypt. yasmine_mohamed@pharm.aun.edu.eg.ORCID http://orcid.org/0009-0008-7374-9334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypervirulent and multidrug-resistant Klebsiella pneumoniae represents a dual threat to global health, combining aggressive virulence with resistance to last-line antibiotics. Conventional therapies are failing, leaving an urgent need for disruptive approaches. Nanotechnology offers transformative solutions by enabling targeted drug delivery, dismantling biofilms, restoring antibiotic potency, and introducing novel modalities such as phage-nanoparticle hybrids and CRISPR-based nanoplatforms. This review synthesizes recent advances in metal-, polymer-, and lipid-based nanostructures designed to combat hvKp, highlighting mechanisms of action, synergistic combinations with antibiotics, and innovative theranostic systems. We also critically examine translational challenges, including reproducibility, safety, and regulatory uncertainty, while outlining future opportunities for precision nanomedicine through smart nanoplatforms, nano-enabled diagnostics, and AI-driven design. By integrating efficacy with safety and clinical feasibility, nanotechnology holds promise to reshape the therapeutic landscape for hvKp and MDR pathogens and contribute to broader strategies against antimicrobial resistance.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeNanomedicineAnimalsDrug Delivery SystemsHumansNanoparticlesVirulenceAnti-Bacterial AgentsAntimicrobial resistance (AMR)Hypervirulent K. pneumoniae (hvKp)Multidrug-resistant bacteria (MDR)NanoparticlesNanotechnology

Identifiers

PMID42799769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.